AR011160A1 - Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada - Google Patents

Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada

Info

Publication number
AR011160A1
AR011160A1 ARP980100780A ARP980100780A AR011160A1 AR 011160 A1 AR011160 A1 AR 011160A1 AR P980100780 A ARP980100780 A AR P980100780A AR P980100780 A ARP980100780 A AR P980100780A AR 011160 A1 AR011160 A1 AR 011160A1
Authority
AR
Argentina
Prior art keywords
incidence
phospholipids
choline
enteral formulation
fatty acid
Prior art date
Application number
ARP980100780A
Other languages
English (en)
Spanish (es)
Original Assignee
Abbott Lab
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Univ Tennessee Res Corp filed Critical Abbott Lab
Publication of AR011160A1 publication Critical patent/AR011160A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ARP980100780A 1997-02-21 1998-02-20 Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada AR011160A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis

Publications (1)

Publication Number Publication Date
AR011160A1 true AR011160A1 (es) 2000-08-02

Family

ID=27122714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100780A AR011160A1 (es) 1997-02-21 1998-02-20 Uso de acido graso poliinsaturado, de fosfolipidos, colina para preparar medicamentos utiles para reducir la incidencia de la enterocolitis necrosante,para la produccion de una formulacion enteral y formulacion enteral mejorada

Country Status (5)

Country Link
US (1) US6080787A (cg-RX-API-DMAC7.html)
JP (1) JP2011137015A (cg-RX-API-DMAC7.html)
KR (1) KR100439166B1 (cg-RX-API-DMAC7.html)
AR (1) AR011160A1 (cg-RX-API-DMAC7.html)
IL (1) IL150490A (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22723A1 (es) * 1997-04-02 2002-02-28 Dalmer Lab Sa Mezcla de ácidos grasos primarios de alto peso molecular obtenidos de la cera de cana de azúcar y sus usos farmacéuticos
EP1090636A1 (en) * 1999-09-13 2001-04-11 Société des Produits Nestlé S.A. High lipid diet
EP1181870A1 (en) * 2000-08-22 2002-02-27 Belovo Eggs & Egg Products Manufactured lipid emulsion having an improved balanced dietary source of vitamin F
EP1372641A4 (en) * 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
US6620427B2 (en) * 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
EP1392278A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPIDREICH FRACTION WITH STEARIDONIC ACID AND GAMMA LINOLIC ACID FROM PLANT SEEDS AND MICROBES
EP1392623A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
US20040013787A1 (en) * 2002-06-28 2004-01-22 Theuer Richard C. Fat compositions for infant formula and methods therefor
KR101195574B1 (ko) * 2002-09-24 2012-10-30 산토리 홀딩스 가부시키가이샤 아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물
DK1589834T3 (da) * 2003-02-05 2007-06-18 Nutricia Nv Enteral komposition til forebyggelse og/eller behandling af sepsis
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
KR20060030860A (ko) * 2003-06-24 2006-04-11 유니버시티 오브 캔사스 메디컬 센터 유아 조제유
EP2324828A1 (en) * 2003-08-18 2011-05-25 BTG International Limited Treatment for neurodegenerative conditions
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
CA2645645C (en) * 2005-05-23 2015-07-14 Massachusetts Institute Of Technology Compositions containing pufa and methods of use thereof
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
KR101578498B1 (ko) * 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
WO2008147562A2 (en) * 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
CN101801200B (zh) * 2007-09-17 2014-10-29 康奈尔大学 用于预防或治疗胃肠病症的支链脂肪酸
EP2258216A1 (en) * 2009-06-02 2010-12-08 Nestec S.A. Nutritional Composition for Supporting Brain Development and Function of Toddlers
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
EP3338784B1 (en) 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
MX388089B (es) 2010-12-31 2025-03-19 Abbott Lab Metodos para usar los oligosacaridos de leche humana para mejorar la salud respiratoria de las vias aereas.
EP2658400A2 (en) 2010-12-31 2013-11-06 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
DK2658399T4 (da) 2010-12-31 2024-03-25 Abbott Lab Ernæringssammensætninger omfattende humane mælkeoligosaccharider til anvendelse i behandling og/eller forebyggelse af enterisk rotavirus-infektion
NZ611807A (en) 2010-12-31 2015-02-27 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
BR112013016929A2 (pt) 2010-12-31 2019-09-24 Abbott Lab oligossacarídeos de leite humano para promover o crescimento de bactérias benéficas
ES2804258T3 (es) 2010-12-31 2021-02-05 Abbott Lab Procedimientos para reducir la incidencia de estrés oxidativo usando oligosacáridos de leche humana, vitamina C y agentes antiinflamatorios
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2014078544A1 (en) * 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
MX2015007935A (es) 2012-12-18 2015-10-09 Abbott Lab Fortificador de leche humana liquido concentrado que contiene proteina hipoalergenica y luteina.
WO2017117121A1 (en) * 2015-12-28 2017-07-06 Abbott Laboratories Nutritional compositions comprising hydrolyzed protein and a modified fat system and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374914D1 (en) * 1982-04-12 1988-01-28 Univ Texas Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) * 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) * 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US4950656A (en) * 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
WO1992012711A1 (en) * 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
DK0784437T3 (da) * 1994-10-05 1999-04-19 Milupa Gmbh & Co Kg Phospholipidholdig fedtblanding med LCP-fedtsyrer
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) * 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US6200624B1 (en) * 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids

Also Published As

Publication number Publication date
KR100439166B1 (ko) 2004-07-07
US6080787A (en) 2000-06-27
JP2011137015A (ja) 2011-07-14
IL150490A (en) 2007-05-15
KR20000075539A (ko) 2000-12-15

Similar Documents

Publication Publication Date Title
AR005556A1 (es) Formula enteral, un suplemento nutricional que contiene una composicion de trigliceridos, trigliceridos, y un procedimiento para preparar esteres de acidos grasos a partir de una mezcla de lipidos
CA1324155C (en) Dietary supplement utilizing omega-3/medium chain triglyceride mixtures
BR9807443A (pt) Processos para reduzir a incidência de enterocolite necrótica em uma criança e para a produção de uma fórmula enteral, e, fórmulas enteral aperfeiçoada contendo ácido araquidÈnico e ácido docosaexaenóico e adequada para alimentar crianças.
US4407821A (en) Lipidic compositions for use in dietetics, reanimation and therapeutics
CL2009000799A1 (es) Composicion de alimento materno que comprende una fuente de lipidos donde los lipidos incluyen al menos un acido graso poliinsaturado de cadena larga seleccionado de: fosfolipidos, fosfatidilcolina, fosfatidiletanolamina, n-acilfosfatidiletanolamina, fosfatidilinositol, fosfatidilserina y/o sus liso derivados; usos.
KR940018091A (ko) 불포화 지방산을 포함하는 처방
RU99119892A (ru) Способы и составы для снижения заболеваемости некротическим энтероколитом (варианты), способ получения состава
RU2005120159A (ru) Водорастворимые концентраты эмульсионного типа
IT9021610A1 (it) Composizioni per il trattamento della pelle contenenti derivati della b-fosfatidilcolina
US6251425B1 (en) Glucoside paucilamellar vesicles
Che et al. Long-term effects of docosahexaenoic acid-bound phospholipids and the combination of docosahexaenoic acid-bound triglyceride and egg yolk phospholipid on lipid metabolism in mice
JP2004505904A (ja) 化粧品において脂質成分として使用する皮脂用調整物
CA2207325A1 (en) Anti-oxidant compositions
DE59803855D1 (de) Hautpflegemittel
JP3081226B2 (ja) 脂肪又は脂肪含有製品の酸化防止方法
Galli et al. Modulation of lipid derived mediators by polyunsaturated fatty acids
EP0409559A2 (en) Pharmaceutical uses of fatty acids
Señoráns et al. Formulations based on milk fat globule membrane as delivery systems for DHA and lutein: effects on lipid composition and immunomodulatory properties
Noble et al. The liver phospholipids of the developing chick embryo
JPH07503014A (ja) 癌の治療におけるカロチノイド類の処方及び用法
Jannace et al. Effects of oral soy phosphatidylcholine on phagocytosis, arachidonate concentrations, and killing by human polymorphonuclear leukocytes
JP2514995B2 (ja) 経皮、経粘膜による物質の吸収を促進する組成物
Ishinaga et al. Perturbation of phospholipid metabolism by erucic acid in male Sprague-Dawley rat heart
Lewis Lipid composition of human bronchial mucus
Alam et al. Excessive intake of 13-cis retinoic acid and fatty acid composition of tissues

Legal Events

Date Code Title Description
FB Suspension of granting procedure